# Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

> **NCT00345878** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 271 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** HPV-16/18 L1 VLP AS04 (Cervarix TM)

## Key facts

- **NCT ID:** NCT00345878
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-25
- **Primary completion:** 2007-12-21
- **Final completion:** 2007-12-21
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345878, "Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00345878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*